Quest Diagnostics (DGX)
NYSE: DGX
· Real-Time Price · USD
179.64
1.20 (0.67%)
At close: Aug 15, 2025, 12:14 PM
Quest Diagnostics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 2.76B | 2.65B | 2.62B | 2.49B | 2.4B | 2.37B | 2.29B | 2.29B | 2.34B | 2.33B | 2.33B | 2.49B | 2.45B | 2.61B | 2.74B | 2.77B | 2.55B | 2.72B |
Cost of Revenue | 1.82B | 1.79B | 1.76B | 1.68B | 1.59B | 1.59B | 1.55B | 1.54B | 1.55B | 1.56B | 1.57B | 1.62B | 1.61B | 1.65B | 1.72B | 1.67B | 1.56B | 1.63B |
Gross Profit | 944M | 863M | 858M | 811M | 804M | 771M | 740M | 754M | 792M | 771M | 758M | 868M | 842M | 965M | 1.03B | 1.1B | 985M | 1.09B |
Operating Income | 425M | 346M | 361M | 330M | 355M | 300M | 267M | 342M | 348M | 305M | 135M | 392M | 388M | 513M | 536M | 652M | 533M | 660M |
Interest Income | n/a | 5M | 7M | 9M | 3M | 6M | 6M | 1M | 2M | 2M | 4M | 4M | 2M | n/a | 1M | n/a | n/a | n/a |
Pretax Income | 393M | 294M | 304M | 302M | 314M | 274M | 245M | 305M | 324M | 282M | 112M | 357M | 327M | 483M | 527M | 680M | 827M | 643M |
Net Income | 281M | 220M | 222M | 226M | 229M | 194M | 192M | 225M | 235M | 202M | 101M | 254M | 233M | 354M | 389M | 503M | 628M | 468M |
Selling & General & Admin | 480M | 476M | 466M | 448M | 406M | 436M | 402M | 380M | 416M | 439M | 563M | 464M | 422M | 425M | 464M | 427M | 429M | 407M |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 39M | 41M | 31M | 33M | 43M | 35M | 71M | 32M | 28M | 27M | 60M | 12M | 32M | 27M | 26M | 25M | 23M | 27M |
Operating Expenses | 519M | 517M | 497M | 481M | 449M | 471M | 473M | 412M | 444M | 466M | 623M | 476M | 454M | 452M | 490M | 452M | 452M | 434M |
Interest Expense | 67M | 72M | 72M | 58M | 47M | 49M | 46M | 41M | 39M | 37M | 36M | 37M | 38M | 37M | 38M | 38M | 38M | 38M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 2.34B | 2.31B | 2.26B | 2.16B | 2.04B | 2.07B | 2.02B | 1.95B | 1.99B | 2.03B | 2.2B | 2.09B | 2.06B | 2.1B | 2.21B | 2.12B | 2.02B | 2.06B |
Income Tax Expense | 97M | 59M | 68M | 65M | 74M | 66M | 40M | 68M | 75M | 65M | -4M | 81M | 77M | 110M | 114M | 153M | 177M | 153M |
Shares Outstanding (Basic) | 112M | 111M | 111M | 112M | 111M | 111M | 112M | 112M | 112M | 112M | 113M | 116M | 117M | 119M | 122M | 123M | 125M | 133M |
Shares Outstanding (Diluted) | 113M | 113M | 113M | 113M | 112M | 112M | 113M | 114M | 114M | 113M | 115M | 118M | 119M | 121M | 125M | 125M | 127M | 135M |
EPS (Basic) | 2.51 | 1.97 | 1.98 | 2.01 | 2.05 | 1.74 | 1.72 | 1.99 | 2.09 | 1.79 | 0.89 | 2.19 | 1.99 | 2.97 | 3.19 | 4.11 | 5.05 | 3.52 |
EPS (Diluted) | 2.47 | 1.94 | 1.95 | 1.99 | 2.04 | 1.72 | 1.70 | 1.96 | 2.05 | 1.78 | 0.88 | 2.15 | 1.96 | 2.93 | 3.12 | 4.02 | 4.96 | 3.46 |
EBITDA | 451M | 488M | 507M | 479M | 478M | 431M | 392M | 451M | 468M | 421M | 261M | 496M | 466M | 595M | 646M | 793M | 955M | 765M |
EBIT | 451M | 348M | 371M | 354M | 361M | 315M | 283M | 340M | 356M | 314M | 145M | 388M | 361M | 489M | 540M | 692M | 855M | 664M |
Depreciation & Amortization | n/a | 140M | 135M | 125M | 117M | 116M | 109M | 111M | 112M | 107M | 116M | 108M | 107M | 106M | 106M | 101M | 100M | 101M |